Virtus ETF Advisers’s Crescent Biopharma, Inc. Common Stock CBIO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q2 | – | Sell |
-603
| Closed | -$138K | – | 467 |
|
|
2020
Q1 | $138K | Sell |
603
-88
| -13% | -$20.1K | 0.06% | 289 |
|
|
2019
Q4 | $366K | Buy |
691
+465
| +206% | +$246K | 0.06% | 281 |
|
|
2019
Q3 | $97K | Sell |
226
-12
| -5% | -$5.15K | 0.02% | 285 |
|
|
2019
Q2 | $284K | Sell |
238
-28
| -11% | -$33.4K | 0.06% | 239 |
|
|
2019
Q1 | $331K | Sell |
266
-33
| -11% | -$41.1K | 0.7% | 52 |
|
|
2018
Q4 | $283K | Buy |
299
+11
| +4% | +$10.4K | 0.05% | 131 |
|
|
2018
Q3 | $415K | Sell |
288
-206
| -42% | -$297K | 0.04% | 151 |
|
|
2018
Q2 | $797K | Buy |
494
+29
| +6% | +$46.8K | 0.7% | 30 |
|
|
2018
Q1 | $755K | Buy |
465
+255
| +121% | +$414K | 0.66% | 83 |
|
|
2017
Q4 | $352K | Sell |
210
-80
| -28% | -$134K | 0.44% | 85 |
|
|
2017
Q3 | $405K | Buy |
290
+27
| +10% | +$37.7K | 0.05% | 108 |
|
|
2017
Q2 | $294K | Buy |
+263
| New | +$294K | 0.04% | 127 |
|